Kailera Therapeutics, Inc. Common Stock (KLRA) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Kailera Therapeutics, Inc. Common Stock (KLRA) has a cash flow conversion efficiency ratio of 0.158x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-68.31 Million) by net assets ($-432.09 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Kailera Therapeutics, Inc. Common Stock balance sheet independence to measure how much of total assets are equity-financed.
Kailera Therapeutics, Inc. Common Stock - Cash Flow Conversion Efficiency Trend (2025–2025)
This chart illustrates how Kailera Therapeutics, Inc. Common Stock's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore Kailera Therapeutics, Inc. Common Stock strategic investment ratio to see how much of total assets are deployed in long-term investments.
Kailera Therapeutics, Inc. Common Stock Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Kailera Therapeutics, Inc. Common Stock ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Greatek Electronics Inc
TW:2441
|
0.062x |
|
Sinbon Electronics Co Ltd
TW:3023
|
0.040x |
|
Fuchs Petrolub SE
XETRA:FPE
|
0.034x |
|
Customers Bancorp, Inc.
NYSE:CUBI
|
0.016x |
|
Sichuan Development Lomon Co Ltd
SHE:002312
|
0.017x |
|
Sejong Telecom Inc
KQ:036630
|
0.017x |
|
GCL System Integration Technology Co Ltd
SHE:002506
|
0.162x |
|
Shenzhen Hymson Laser Intelligent Equipments Co Ltd
SHG:688559
|
0.057x |
Annual Cash Flow Conversion Efficiency for Kailera Therapeutics, Inc. Common Stock (2025–2025)
The table below shows the annual cash flow conversion efficiency of Kailera Therapeutics, Inc. Common Stock from 2025 to 2025. For the full company profile with market capitalisation and key ratios, see KLRA company net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $-356.46 Million | $-120.21 Million | 0.337x | -- |
About Kailera Therapeutics, Inc. Common Stock
Kailera Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company developing therapies for obesity and related conditions. The company develops clinical- and preclinical-stage therapies, with a product pipeline that includes injectable peptides, oral peptides, and oral small molecules. Key programs include KAI-9531, an injectable GLP-1/GIP receptor dual agonist; KAI-7535, an oral … Read more